The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
Visit from the Hospital Israelita Albert Einstein, São Paulo, Brazil17/02/2020 – 19/02/2020
The Screening Group (SCR) team participated in meetings with representative of the Sociedade Beneficente Israelita Brasileira Albert Einstein and the Einstein Friends of Oncology and Hematology (AMIGOH) to discuss mutual collaboration in areas of cancer prevention, screening, artificial intelligence, big data, development of Latin American Code Against Cancer and training opportunities.
WHO cancer strategy technical support mission, Beirut, Lebanon10/02/2020 – 12/02/2020
Dr Partha Basu participated to the WHO-IARC-IAEA Cancer review Lebanon mission.
Conference: Harms and benefits of evidence-based screening outlined in new WHO report, Copenhagen, Denmark11/02/2020 – 12/02/2020
Dr Andre Carvalho participated in this WHO-Euro conference on screening that was organized in the framework of a WHO European initiative aimed at improving decision-making related to screening practices to maximize benefits and minimize harms. .
View the meeting summary.
New publication: Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm12/02/2020
In this publication edited by the WHO Regional Office for Europe, the authors described various aspects policy-makers should consider before starting, continuing or stopping a screening programme and the operational, monitoring and evaluation aspects of implementation. This guide forms part of WHO’s efforts to increase the effectiveness of screening programmes within the region, maximizing benefits and minimizing harm.
View the publication.
New publication: Screening. When is it appropriate and how can we get it right?11/02/2020
In this publication edited by the European Observatory on Health Systems and Policies and the WHO Regional Office for Europe, the authors start by explaining the core components of a screening programme, highlighting that, while seemingly simple, putting together all elements of a screening programme is very complex. They then ask when screening should be done, emphasizing the continued relevance of Wilson & Jungner’s screening principles. When screening is appropriate, evidence is presented on how to achieve optimal results. This brief is an essential reading for anybody involved in the decisions on screening or its provision. View the publication.
|Ponti A., Basu P., Ritchie D., Anttila A., Carvalho A.L., Senore C., Mallafre-Larrosa M., Piccinelli C., Ronco G., Soerjomataram I., Primic-Žakelj M., Dillner J., Elfstrom M.K., Lonnberg S., Vale D.B., Tomatis M., Armaroli P., Giordano L., Sankaranarayanan R., Segnan N. Key issues that need to be considered while revising the current Annex of the European Council Recommendation (2003) on cancer screening. Int J Cancer. 2020 Jan 22.|
|Zhao X.L., Xu X.Q., Duan X.Z., Rezhake R., Hu S.Y., Wang Y., Xia C.F., Zhang X., Qiao Y.L., Sankaranarayanan R., Zhao F.H., Basu P. Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China. Int J Cancer. 2020 Jan 22.|
|Whitworth H.S., Gallagher K.E., Howard N., Mounier-Jack S., Mbwanji G., Kreimer A.R., Basu P., Kelly H., Drolet M., Brisson M., Watson-Jones D. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2019 Dec 20. pii: S0264-410X(19)31659-7.|